1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. AVROBIO, Inc.
  6. News
  7. Summary
    AVRO   US05455M1009

AVROBIO, INC.

(AVRO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Barclays Adjusts AVROBIO's Price Target to $6 From $22, Reiterates Overweight Rating

01/05/2022 | 06:18am EDT


© MT Newswires 2022
All news about AVROBIO, INC.
05/18AVROBIO Announces Preclinical Gene Therapy Data for Pompe Disease at American Society o..
BU
05/18AVROBIO, Inc. Announces Preclinical Data Demonstrating the Efficacy and Safety of AVR-R..
CI
05/17Needham Adjusts AVROBIO's Price Target to $6 from $8, Keeps Buy Rating
MT
05/17AVROBIO, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
05/17AVROBIO Reports Positive Data From Phase 1/2 Clinical Trial of Investigational Gene The..
BU
05/17Avrobio Reports Positive Data from Phase 1/2 Clinical Trial of Investigational Gene The..
CI
05/16AVROBIO to Present at the H.C. Wainwright Global Investment Conference
BU
05/11Barclays Adjusts AVROBIO's Price Target to $4 from $6, Keeps Overweight Rating
MT
05/10AVROBIO, INC. Management's Discussion and Analysis of Financial Condition and Results ..
AQ
05/10AVROBIO Reports First Quarter 2022 Financial Results and Provides Business Update
BU
More news
Analyst Recommendations on AVROBIO, INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -110 M - -
Net cash 2022 78,7 M - -
P/E ratio 2022 -0,34x
Yield 2022 -
Capitalization 33,8 M 33,8 M -
EV / Sales 2022 -
EV / Sales 2023 -
Nbr of Employees 122
Free-Float 97,4%
Chart AVROBIO, INC.
Duration : Period :
AVROBIO, Inc. Technical Analysis Chart | AVRO | US05455M1009 | MarketScreener
Technical analysis trends AVROBIO, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Last Close Price 0,79 $
Average target price 4,57 $
Spread / Average Target 478%
EPS Revisions
Managers and Directors
Geoff MacKay President, Chief Executive Officer & Director
Erik John Ostrowski Chief Financial Officer & Treasurer
Bruce Lee Booth Chairman
Christopher Mason Chief Scientific Officer
Kim Raineri Chief Manufacturing & Technical Operations Officer
Sector and Competitors
1st jan.Capi. (M$)
AVROBIO, INC.-79.45%34
GILEAD SCIENCES, INC.-12.08%79 360
REGENERON PHARMACEUTICALS, INC.4.69%70 805
VERTEX PHARMACEUTICALS17.76%65 333
WUXI APPTEC CO., LTD.-16.92%41 354
BIONTECH SE-34.88%40 796